{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:48:54Z","timestamp":1789858134015,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1462-2","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T11:46:34Z","timestamp":1511351194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-7832","authenticated-orcid":false,"given":"Gerd","family":"Horneff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Carina","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Klotsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Hospach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Foeldvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Trauzeddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weller-Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Perter","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"1462_CR1","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.3899\/jrheum.150997","volume":"43","author":"G Janow","year":"2016","unstructured":"Janow G, Schanberg LE, Setoguchi S, Hasselblad V, Mellins ED, Schneider R, Kimura Y, the CARRA Legacy Registry Investigators. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010\u20132013. J Rheumatol. 2016;43:1755\u201362.","journal-title":"J Rheumatol"},{"issue":"9563","key":"1462_CR2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767\u201378.","journal-title":"Lancet"},{"key":"1462_CR3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-1-4160-6581-4.10006-8","volume-title":"Textbook of pediatric rheumatology","author":"NT Ilowite","year":"2011","unstructured":"Ilowite NT, Laxer RM. Pharmacology and drug therapy. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier; 2011. p. 71\u2013126.","edition":"6"},{"key":"1462_CR4","first-page":"935","volume":"32","author":"Y Kimura","year":"2005","unstructured":"Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005;32:935\u201342.","journal-title":"J Rheumatol."},{"key":"1462_CR5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/kem271","volume":"47","author":"M Frosch","year":"2008","unstructured":"Frosch M, Roth J. New insights in systemic juvenile idiopathic arthritis\u2013from pathophysiology to treatment. Rheumatology (Oxford). 2008;47:121\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"1462_CR6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/art.24349","volume":"60","author":"M Frosch","year":"2009","unstructured":"Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D, Roth J. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:883\u201391.","journal-title":"Arthritis Rheum."},{"key":"1462_CR7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/annrheumdis-2012-201388","volume":"71","author":"A Martini","year":"2012","unstructured":"Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis. 2012;71:1437\u20139.","journal-title":"Ann Rheum Dis."},{"key":"1462_CR8","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ, PRINTO; PRCSG. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396\u2013406.","journal-title":"N Engl J Med"},{"key":"1462_CR9","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F Benedetti De","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A, PRINTO, PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385\u201395.","journal-title":"N Engl J Med."},{"key":"1462_CR10","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998\u20131006.","journal-title":"Lancet."},{"key":"1462_CR11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747\u201354.","journal-title":"Ann Rheum Dis."},{"key":"1462_CR12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","volume":"64","author":"EM DeWitt","year":"2012","unstructured":"DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll ML, Angeles-Han S, Milojevic D, Schikler KN, Vehe RK, Weiss JE, Weiss P, Ilowite NT, Wallace CA, Juvenile Idiopathic Arthritis Disease-specific Research Committee of Childhood Arthritis Rheumatology and Research Alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012;64:1001\u201310.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1462_CR13","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","volume":"63","author":"G Horneff","year":"2004","unstructured":"Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, K\u00fcster RM, Michels H, Moebius D, Rogalski B, Thon A, Paediatric Rheumatology Collaborative Group. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1638\u201344.","journal-title":"Ann Rheum Dis"},{"key":"1462_CR14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","volume":"68","author":"G Horneff","year":"2009","unstructured":"Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68:519\u201325.","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 23","key":"1462_CR15","first-page":"S1","volume":"19","author":"N Ruperto","year":"2001","unstructured":"Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, Tortorelli A, Landgraf JM, Singh G, Martini A, Paediatric Rheumatology International Trials Organisation. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol. 2001;19(4 Suppl 23):S1\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"4 Suppl 23","key":"1462_CR16","first-page":"S71","volume":"19","author":"I Foeldvari","year":"2001","unstructured":"Foeldvari I, Ruperto N, Dressler F, H\u00e4fner R, K\u00fcster RM, Michels H, Minden K, Schauer-Petrowskaja C, Bullinger M, Landgraf JM, Huppertz HI, Paediatric Rheumatology International Trials Organisation. The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol. 2001;19(4 Suppl 23):S71\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"1462_CR17","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A, Paediatric Rheumatology International Trials Organisation. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658\u201366.","journal-title":"Arthritis Rheum."},{"key":"1462_CR18","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/art.34373","volume":"64","author":"A Consolaro","year":"2012","unstructured":"Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, Pederzoli S, Dav\u00ec S, Martini A, Ravelli A, Paediatric Rheumatology International Trials Organization. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012;64:2366\u201374.","journal-title":"Arthritis Rheum"},{"key":"1462_CR19","first-page":"2290","volume":"31","author":"CA Wallace","year":"2004","unstructured":"Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for selected categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290\u20134.","journal-title":"J Rheumatol."},{"key":"1462_CR20","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202\u20139.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"1462_CR21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.39407","volume":"68","author":"AA Grom","year":"2016","unstructured":"Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, Ruperto N, Leon K, Lheritier K, Abrams K, Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol. 2016;68(1):218\u201328.","journal-title":"Arthritis Rheumatol"},{"key":"1462_CR22","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3899\/jrheum.130690","volume":"41","author":"S Yokota","year":"2014","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. Rheumatology. 2014;41:759\u201367.","journal-title":"Rheumatology."},{"key":"1462_CR23","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","volume":"75","author":"S Yokota","year":"2016","unstructured":"Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M, Tanaka K, Minota S. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1\u00a0year of post marketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75:1654\u201360.","journal-title":"Ann Rheum Dis."},{"key":"1462_CR24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/annrheumdis-2015-eular.6550","volume":"74","author":"F Benedetti De","year":"2015","unstructured":"De Benedetti F, Ruperto N, Brunner H, Keane C, Wells C, Wang J, Calvo I, Cuttica R, Ravelli A, Schneider R, Eleftheriou D, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Martini A, Lovell D. THU0508\u2005safety and efficacy of tocilizumab in patients with systemic juvenile idiopathic arthritis: 5-year data from Tender, a phase 3 clinical trial. Ann Rheum Dis. 2015;74:384.","journal-title":"Ann Rheum Dis."},{"key":"1462_CR25","doi-asserted-by":"crossref","unstructured":"Brunner HI, Ruperto N, Quartier P, Constantin T, Alexeeva E, Kon\u00e9-Paut I, Marzan K, Wulffraat N, Schneider R, Padeh S, Chasnyk V, Wouters C, Kuemmerle-Deschner JB, Kallinich T, Lauwerys B, Haddad E, Nasonov E, Trachana M, Vougiouka O, Leon K, Speziale A, Lheritier K, Martini A, Lovell D. Efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis: results from the phase 3 extension study [abstract]. Arthritis Rheumatol. 2015;67(suppl 10)","DOI":"10.1136\/annrheumdis-2015-eular.2050"},{"key":"1462_CR26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, Birmingham J, Eggebeen A, Janssen E, Shulman AI, Son MB, Hong S, Jones K, Ilowite NT, Cron RQ, Higgins GC. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545\u201355.","journal-title":"Arthritis Rheum."},{"key":"1462_CR27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","volume":"73","author":"G Horneff","year":"2014","unstructured":"Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, Dehoorne J, Panaviene V, Susic G, Stanevica V, Kobusinska K, Zuber Z, Mouy R, Rumba-Rozenfelde I, Breda L, Dolezalova P, Job-Deslandre C, Wulffraat N, Alvarez D, Zang C, Wajdula J, Woodworth D, Vlahos B, Martini A, Ruperto N, for the Paediatric Rheumatology International Trials Organisation (PRINTO). Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73:1114\u201322.","journal-title":"Ann Rheum Dis"},{"key":"1462_CR28","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.21885","volume":"54","author":"DJ Lovell","year":"2006","unstructured":"Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore JB, White B, Giannini EH, Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54:1987\u201394.","journal-title":"Arthritis Rheum"},{"key":"1462_CR29","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"HI Brunner","year":"2015","unstructured":"Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-P\u00e9rez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, G\u00e1mir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F, Paediatric Rheumatology International Trials Organisation PRINTO, Pediatric Rheumatology Collaborative Study Group (PRCSG). Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1462_CR30","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","volume":"13","author":"MH Schiff","year":"2011","unstructured":"Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13:R141.","journal-title":"Arthritis Res Ther."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1462-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T11:30:41Z","timestamp":1751023841000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1462-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1462"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1462-2","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,22]]},"article-number":"256"}}